Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders

Haematologica

Volumn 88, Issue 10, 2003, Pages 1123-1129

  Passamonti, Francesco ^a   Vanelli, Laura ^a   Malabarba, Lucia ^a   Rumi, Elisa ^a   Pungolino, Ester ^b   Malcovati, Luca ^a   Pascutto, Cristiana ^a   Morra, Enrica ^b   Lazzarino, Mario ^a   Cazzola, Mario ^a,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

CD34 positive cell; Essential thrombocythemia; Myelofibrosis with myeloid metaplasia; Myeloproliferative disorder; Polycythemia vera

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ARTICLE; CELL ASSAY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; STEM CELL; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BIOLOGICAL MARKERS; CELL COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0242299235     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-65.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-70.
3. Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999;104:730-7.
4. Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000;95:2569-76.
5. Teofili L, Martini M, Luongo M, Di Mario A, Leone G, De Stefano V, et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J Clin Oncol 2002; 20:4249-54.
6. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-51.
7. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986;23:177-82.
8. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-90.
9. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003;101:3294-301.
10. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, Van Der Maas AP, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003.
11. Passamonti F, Malabarba L, Orlandi E, Barate C, Canevari A, Brusamolino E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003;88:13-8.
12. Passamonti F, Malabarba L, Orlandi E, Pascutto C, Brusamolino E, Astori C, et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002;116:855-61.
13. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-55.
14. Andreasson B, Swolin B, Kutti J. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2000;64:188-93.
15. Andreasson B, Swolin B, Kutti J. Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol 1997;59:171-6.
16. Andreasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2002; 68:189-93.
17. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ, et al. Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. Hematology (Am Soc Hematol Educ Program) 2000:51-68.
18. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29-39.
19. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70.
20. Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, et al. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry 2000;42:327-46.
21. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996;87:1-13.
22. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003;102:1249-53.
23. Ponchio L, Eaves C, Hogge D, Perotti C, Torretta L, Cerani P, et al. Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF. Br J Haematol 1997;99:394-402.
24. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984;57:495-503.
25. Douer D, Fabian I, Cline MJ. Circulating pluripotent haemapoietic cells in patients with myeloproliferative disorders. Br J Haematol 1983;54:373-81.
26. Fuchigami K, Mori H, Matsuo T, Iwanaga M, Nagai K, Kuriyama K, et al. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodys-plastic syndromes identified by highly sensitive flow cytometry. Leuk Res 2000;24:163-74.
27. Maynadie M, Gerland L, Aho S, Girodon F, Bernier M, Brunet C, et al. Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia. Haematologica 2002;87:795-803.
28. Barosi G, Polino G. Chronic myelofibrosis with myeloid metaplasia. The spectrum of clinical syndromes. Haematologica 1987;72:553-62.